AIM: The aim of the study was to examine mortality risk associated with use of antidepressants and antipsychotics classified with torsades de pointes (TdP) risk in elderly. METHODS: A matched case-control register study was conducted in people 65 years and older dying outside hospital from 2008-2013 (n = 286,092) and matched controls (n = 1,430,460). The association between prescription of antidepressants and antipsychotics with various TdP risk according to CredibleMeds (www.crediblemeds.org) and all-cause mortality was studied by multivariate conditional logistic regression adjusted for comorbidity and several other confounders. RESULTS: Use of antidepressants classified with known or possible TdP risk, was associated with higher adjusted risk for mortality (OR 1.53, 95% CI 1.51, 1.56 and OR 1.63, 95% CI 1.61, 1.67, respectively) compared with antidepressants classified with conditional TdP risk (OR 1.25, 95% CI 1.22, 1.28) or without TdP classification (OR 0.99, 95% CI 0.94, 1.05). Antipsychotics classified with known TdP risk were associated with higher risk (OR 4.57, 95% CI 4.37, 4.78) than antipsychotics with possible risk (OR 2.58, 95% CI 2.52, 2.64) or without TdP classification (OR 2.14, 95% CI 2.03, 2.65). The following risk ranking was observed for commonly used antidepressants: mirtazapine > citalopram > sertraline > amitriptyline and for antipsychotics: haloperidol > risperidone >olanzapine > quetiapine. CONCLUSION: The CredibleMeds system predicted drug-associated risk for mortality in the elderly at the risk class level. Among antipsychotics, haloperidol, and among antidepressants, mirtazapine and citalopram, were associated with the highest risks. The results suggest that the TdP risk with antidepressants and antipsychotics should be taken into consideration when prescribing to the elderly.
AIM: The aim of the study was to examine mortality risk associated with use of antidepressants and antipsychotics classified with torsades de pointes (TdP) risk in elderly. METHODS: A matched case-control register study was conducted in people 65 years and older dying outside hospital from 2008-2013 (n = 286,092) and matched controls (n = 1,430,460). The association between prescription of antidepressants and antipsychotics with various TdP risk according to CredibleMeds (www.crediblemeds.org) and all-cause mortality was studied by multivariate conditional logistic regression adjusted for comorbidity and several other confounders. RESULTS: Use of antidepressants classified with known or possible TdP risk, was associated with higher adjusted risk for mortality (OR 1.53, 95% CI 1.51, 1.56 and OR 1.63, 95% CI 1.61, 1.67, respectively) compared with antidepressants classified with conditional TdP risk (OR 1.25, 95% CI 1.22, 1.28) or without TdP classification (OR 0.99, 95% CI 0.94, 1.05). Antipsychotics classified with known TdP risk were associated with higher risk (OR 4.57, 95% CI 4.37, 4.78) than antipsychotics with possible risk (OR 2.58, 95% CI 2.52, 2.64) or without TdP classification (OR 2.14, 95% CI 2.03, 2.65). The following risk ranking was observed for commonly used antidepressants: mirtazapine > citalopram > sertraline > amitriptyline and for antipsychotics: haloperidol > risperidone >olanzapine > quetiapine. CONCLUSION: The CredibleMeds system predicted drug-associated risk for mortality in the elderly at the risk class level. Among antipsychotics, haloperidol, and among antidepressants, mirtazapine and citalopram, were associated with the highest risks. The results suggest that the TdP risk with antidepressants and antipsychotics should be taken into consideration when prescribing to the elderly.
Authors: Björn Wettermark; Niklas Hammar; Carl Michael Fored; C MichaelFored; Andrejs Leimanis; Petra Otterblad Olausson; Ulf Bergman; Ingemar Persson; Anders Sundström; Barbro Westerholm; Måns Rosén Journal: Pharmacoepidemiol Drug Saf Date: 2007-07 Impact factor: 2.890
Authors: W Victor R Vieweg; Mehrul Hasnain; Robert H Howland; John M Hettema; Christopher Kogut; Mark A Wood; Ananda K Pandurangi Journal: Am J Med Date: 2012-06-27 Impact factor: 4.965
Authors: Helen C Kales; Marcia Valenstein; H Myra Kim; John F McCarthy; Dara Ganoczy; Francesca Cunningham; Frederic C Blow Journal: Am J Psychiatry Date: 2007-10 Impact factor: 18.112
Authors: W Victor R Vieweg; Jules C Hancox; Mehrul Hasnain; Jayanthi N Koneru; Michael Gysel; Adrian Baranchuk Journal: Ther Adv Infect Dis Date: 2013-08
Authors: Susanna M Wallerstedt; Johan Fastbom; Kristina Johnell; Christina Sjöberg; Sten Landahl; Anders Sundström Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Tarita Murray-Thomas; Meghan E Jones; Deven Patel; Elizabeth Brunner; Chetan C Shatapathy; Stephen Motsko; Tjeerd P Van Staa Journal: Cardiovasc Psychiatry Neurol Date: 2013-12-26
Authors: Raymond L Woosley; Klaus Romero; Craig W Heise; Tyler Gallo; Jared Tate; Raymond David Woosley; Sophie Ward Journal: Drug Saf Date: 2017-06 Impact factor: 5.606
Authors: Meng Wang; Barbara Szepietowska; Bronislava Polonsky; Scott McNitt; Arthur J Moss; Wojciech Zareba; David S Auerbach Journal: Am J Cardiol Date: 2017-11-13 Impact factor: 2.778
Authors: A Biffi; F Rea; L Scotti; A Mugelli; E Lucenteforte; A Bettiol; A Chinellato; G Onder; C Vitale; N Agabiti; G Trifirò; G Roberto; G Corrao Journal: Eur J Clin Pharmacol Date: 2017-10-18 Impact factor: 2.953
Authors: Elizabeth Marie Gavioli; Alfred Burger; Aia Gamaleldin; Nourhan Eladghm; Etty Vider Journal: Support Care Cancer Date: 2022-04-26 Impact factor: 3.603